Dagens aktienyheder med Ascelia Pharma og ExpreS2ion Biotech

Dagens aktienyheder med Scandinavian Medical Solutions, GomSpace og Ascelia Pharma AB

Dagens aktienyheder med ExpreS2ion Biotechnologies og Ascelia Pharma

Dagens aktienyheder med ExpreS2ion Biotech, Impero, SKAKO, MapsPeople og Ascelia Pharma

Wrap-Up from Interview with Deputy CEO Julie Waras Brogren

Meet and ask questions to Deputy CEO Julie Waras Brogren from Ascelia Pharma on 11 November at 2.00 PM. During the third quarter, Ascelia Pharma successfully completed its capital increase, allowing the company to focus on preparations for submitting the NDA for Orviglance and engaging with potential partners. In the last quarter of the year (Q4), Ascelia will receive the complete data package from the Orviglance SPARKLE Phase 3 study. Additionally, they will participate in the annual Radiological Society of North America conference in Chicago from December 1-5, 2024, where they will present abstracts from the SPARKLE study in an oral presentation.

Dagens aktienyheder med TORM, Gubra, Asetek, Ascelia Pharma, WindowMaster og Columbus

Full Study Report Reinforcing the Successful Outcomes of Orviglance Phase 3 Study SPARKLE.

Dagens aktienyheder med ExpreS2ion Biotechnologies, Ascelia Pharma og Aktier med Friis